Assets Acquisition (Details) ¥ in Millions |
12 Months Ended | |||
|---|---|---|---|---|
|
Jun. 30, 2026
USD ($)
|
Jun. 30, 2026
CNY (¥)
|
Jun. 30, 2025
USD ($)
|
Nov. 05, 2024 |
|
| Assets Acquisition [Line Items] | ||||
| Impairment of intangible assets | ||||
| Hupan Pharmaceutical (Hubei) Co., Ltd [Member] | ||||
| Assets Acquisition [Line Items] | ||||
| Equity interests | 100.00% | |||
| Hubei Huayao Pharmaceutical Co., Ltd [Member] | ||||
| Assets Acquisition [Line Items] | ||||
| Total consideration | $ 552,730 | ¥ 4.0 | ||
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Percentage of equity in the acquiree held by the acquirer immediately before the acquisition date in a business combination. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of impairment loss for finite- and indefinite-lived intangible assets and capitalized cost for software to be sold, leased, or marketed. Excludes goodwill. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|